EP Patent

EP4626890A1 — Ribociclib salts and formulations thereof

Assigned to KRKA dd · Expires 2025-10-08 · 1y expired

What this patent protects

29 KRK0017-WO Abstract: The invention relates to physiologically acceptable acid addition salts of Ribociclib and pharmaceutical compositions thereof. In particular, the invention relates to tablet formulations containing Ribociclib malate monohydrate, Ribociclib hydrochloride di…

USPTO Abstract

29 KRK0017-WO Abstract: The invention relates to physiologically acceptable acid addition salts of Ribociclib and pharmaceutical compositions thereof. In particular, the invention relates to tablet formulations containing Ribociclib malate monohydrate, Ribociclib hydrochloride dihydrate or Ribociclib hydrochloride anhydrate.

Drugs covered by this patent

Patent Metadata

Patent number
EP4626890A1
Jurisdiction
EP
Classification
Expires
2025-10-08
Drug substance claim
No
Drug product claim
No
Assignee
KRKA dd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.